Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Boussageon R, et al. Among authors: erpeldinger s. BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169. BMJ. 2011. PMID: 21791495 Free PMC article. Review.
GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.
Grenet G, Ribault S, Nguyen GB, Glais F, Metge A, Linet T, Kassai-Koupai B, Cornu C, Bejan-Angoulvant T, Erpeldinger S, Boussageon R, Gouraud A, Bonnet F, Cucherat M, Moulin P, Gueyffier F. Grenet G, et al. Among authors: erpeldinger s. PLoS One. 2019 Jun 25;14(6):e0217701. doi: 10.1371/journal.pone.0217701. eCollection 2019. PLoS One. 2019. PMID: 31237921 Free PMC article.
The IDEAL study : towards personalized drug treatment of hypertension.
Bejan-Angoulvant T, Baguet JP, Erpeldinger S, Boivin JM, Mercier A, Leftheriotis G, Gagnol JP, Fauvel JP, Giraud C, Bricca G, Gueyffier F; IDEAL Study Group. Bejan-Angoulvant T, et al. Among authors: erpeldinger s. Therapie. 2012 May-Jun;67(3):195-204. doi: 10.2515/therapie/2012031. Epub 2012 Aug 9. Therapie. 2012. PMID: 22874485 Clinical Trial.
Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial.
Gueyffier F, Subtil F, Bejan-Angoulvant T, Zerbib Y, Baguet JP, Boivin JM, Mercier A, Leftheriotis G, Gagnol JP, Fauvel JP, Giraud C, Bricca G, Maucort-Boulch D, Erpeldinger S; IDEAL Trial Group. Gueyffier F, et al. Among authors: erpeldinger s. J Hum Hypertens. 2015 Jan;29(1):22-7. doi: 10.1038/jhh.2014.29. Epub 2014 Apr 17. J Hum Hypertens. 2015. PMID: 24739801 Clinical Trial.
Physicians' knowledge and practice of lung cancer screening: a cross-sectional survey comparing general practitioners, thoracic oncologists, and pulmonologists in France.
Couraud S, Girard N, Erpeldinger S, Gueyffier F, Devouassoux G, Llorca G, Souquet PJ; Lyon Lung Cancer Screening Workgroup. Couraud S, et al. Among authors: erpeldinger s. Clin Lung Cancer. 2013 Sep;14(5):574-80. doi: 10.1016/j.cllc.2013.05.003. Epub 2013 Jul 3. Clin Lung Cancer. 2013. PMID: 23830707
12 results